ESTRO 35 2016 S621 ________________________________________________________________________________ administered in escalating doses to cohorts of three patients at each dose level. Phase II was then assessed at the selected maximum tolerated dose (MTD). The patients were monitored for acute toxicity using the Common Toxicity Criteria, version 3.0 and late toxicity using the RTOG/EORTC.tween November 2008 and March 2015, a total of 36 patients with primary carcinoma of the cervix, FIGO stage IB1 to IIIB, confirmed by histology, negative para-aortic lymph nodes were enrolled into this phase I / II trial. Chemotherapy agents were administered in escalating doses to cohorts of three patients at each dose level. Phase II was then assessed at the selected maximum tolerated dose (MTD). The patients were monitored for acute toxicity using the Common Toxicity Criteria, version 3.0 and late toxicity using the RTOG/EORTC.
Results:
Of the 36 patients, 18 enrolled on phase I study. The MTD was confirmed to be paclitaxel 40mg/m2 and cisplatin 40mg/m2 administered weekly for six cycles with 3D conformal external beam radiotherapy. There were additional 18 evaluable patients for the phase II analysis，yielding a total of 21 patients at the MTD. 3° (9/21) hematologic, principally neutropenia, occurs late cycles. All patients finished 5-6 cycles chemotherapy and radiotherapy in 7 weeks. The median follow-up was 24 months (5-58). At 4 months, 18 CR (1 pCR), 3 PR. At 24 months local control rate was 90.4 %（19/21）. 18/21 patients (85.7％) are still survive ( 1 was loss of follow-up). 2 of 2 recurrent or metastasis patients have died. Late toxicities did not appear during follow-up.
Conclusion:
Combination PTX and DDP administered concurrently with pelvic EBRT can be safely administered at the MTD of DDP 40 mg/m2 and PTX 40 mg/m2 weekly for six cycles in Chinese women. Primary result showed a good clinical outcome. We need continue follow-up. Further development to determine if the combination will help yield a survival benefit.
EP-1326
The role of PET CT in the IMRT of cervical cancer: the experience of the Institute of Candiolo G. Cattari 
Material and Methods:
From June 2010 to October 2015, 38 patients (pts) with cervical cancer were treated by radiotherapy, 21 with curatively (4 recurrences) and 17 with postoperatively (5 with positive margins). The mean age was 58 years (range 32-88). The histology was: squamous cell carcinoma (26 pts), adenocarcinoma (9 pts), adenosquamous carcinoma (3 pts). The grading was: G3 in 14 pts, G2 in 23 pts, G1 in 1 pt. The FIGO stage was: IB1 in 7 pts, IB2 in 3 pts, IIA1 in 5 pts, IIA2 in 2 pts, IIB in 13 pts, IIIA in 2 pts, IIIB in 2 pts, IIIB2 in 1 pt, IIIC2 in 1 pt and IVA in 2 pts. 24 pts received concurrent chemotherapy (CHT), 3 neoadjuvant CHT and 1 neoadjuvant and concomitant CHT. 3 pts were treated with IMRT by LINAC, 34 pts with image-guided IMRT-SB-IGRT using Helical Tomotherapy; 1 patient received exclusive High Dose Rate (HDR) brachytherapy. Tumor doses were ranged from 54 to 70.4 Gy in 30-32 fractions (fr); dose to the pelvis were from 50.4 to 54 Gy / 25-30 fr. In 5 pts was treated lumbaraortic chain (51 Gy/30 fr); 14 pts received a boost on PET positive lymph nodes with dose range from 54 to 66 Gy/30 fr). 24 pts were treated with HDR boost with dose/fraction of 6-15 Gy in 1-3 frs.
Results: 37 pts received a PET-CT to staging and planning (Philips GEMINI TF), 33 of these had a PET-CT evaluation post RT. PET -CT changed the previous stage of disease in 6/37 cases (16%). 33 pts received also Magnetic Resonance (MRI) to staging, of these 10 showed positive lymph-nodes, conversely PET CT showed positive nodes in 20 pts (20%). 26 pts underwent a PET CT after RT: 18 pts showed a complete response (CR), 7 a partial response (PR), 1 pt a local persistence of lesion and a distance progression disease (PD). The time from end of treatment to PET evaluation was variable from 1 to 15 months (mean 4.3 months). About 6 pts with PR, 3 showed CR at the following PET-CT (8,12 and 14 months), 1 local stable disease (SD) and distance metastases and 2 showed local and distance PD.
Conclusion: FDG-PET changed tumor stage in 6/37 cases (16%) allowing a dose escalation on lymph-nodes detected and finally showed to be a sensitive and reliable method in the evaluation of radio-chemotherapy treatment response. The optimal timing of execution remains to be defined by further studies.
